IQVIA Laboratories offers a full range of bioanalytical and ADME services to deliver reliable data that are consistent with the highest industry standards. Presented at the 2016 Delaware Valley Drug Metabolism Discussion Group meeting in collaboration with Hμrel® corporation, this presentation describes efforts to compare suspension, plated monoculture and Hμrel® co-culture hepatocyte models for estimated clearance of low-turnover drugs and metabolite generation comparisons. It also covers work that was done with Optivia Corporation to develop an integrated approach to more accurately assess cholestatic liability of drugs.
Download the presentation to learn more.
Author:
J Matthew Hutzler, Ph.D., Director of In Vitro Metabolism, Bioanalytical and ADME Labs
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Hybrid Assays for Protein Bioanalysis
Assays and Why Are They Essential for Protein Bioanalysis?
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
High Throughput ADME Testing
Minimizing turnaround time for ADME assays
ADME Services
Accelerating your drug discovery, preclinical and clinical programs with ADME services
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
Early Hit-to-Lead ADME Screening Bundle
Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
High Throughput ADME Screening Services
Capabilities that accelerate preclinical studies
IND-Enabling Bundle of In Vitro Assays to Assess Drug-Drug Interaction Risk
DDI Fact Sheet
